- Home
- VRTX vs BMY Comparison
VRTX vs BMY Comparison
Compare VRTX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- BMY
- Stock Information
- Founded
- VRTX 1989
- BMY 1887
- Country
- VRTX United States
- BMY United States
- Employees
- VRTX N/A
- BMY N/A
- Industry
- VRTX EDP Services
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- VRTX Technology
- BMY Health Care
- Exchange
- VRTX Nasdaq
- BMY Nasdaq
- Market Cap
- VRTX 96.6B
- BMY 94.0B
- IPO Year
- VRTX 1991
- BMY N/A
- Fundamental
- Price
- VRTX $423.53
- BMY $43.73
- Analyst Decision
- VRTX Buy
- BMY Hold
- Analyst Count
- VRTX 26
- BMY 14
- Target Price
- VRTX $491.78
- BMY $57.54
- AVG Volume (30 Days)
- VRTX 1.4M
- BMY 17.4M
- Earning Date
- VRTX 11-03-2025
- BMY 10-30-2025
- Dividend Yield
- VRTX N/A
- BMY 5.66%
- EPS Growth
- VRTX N/A
- BMY N/A
- EPS
- VRTX 14.07
- BMY 2.49
- Revenue
- VRTX $11,418,800,000.00
- BMY $47,704,000,000.00
- Revenue This Year
- VRTX $10.92
- BMY N/A
- Revenue Next Year
- VRTX $9.55
- BMY N/A
- P/E Ratio
- VRTX $30.04
- BMY $17.63
- Revenue Growth
- VRTX 10.46
- BMY 2.57
- 52 Week Low
- VRTX $362.50
- BMY $42.96
- 52 Week High
- VRTX $519.88
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- VRTX 61.96
- BMY 42.33
- Support Level
- VRTX $405.54
- BMY $43.52
- Resistance Level
- VRTX $432.76
- BMY $45.23
- Average True Range (ATR)
- VRTX 8.97
- BMY 0.73
- MACD
- VRTX 1.62
- BMY 0.06
- Stochastic Oscillator
- VRTX 71.05
- BMY 29.25
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.